KR102878718B1 - Bet v 1에 대한 인간 항체 및 이것의 사용 방법 - Google Patents

Bet v 1에 대한 인간 항체 및 이것의 사용 방법

Info

Publication number
KR102878718B1
KR102878718B1 KR1020247018848A KR20247018848A KR102878718B1 KR 102878718 B1 KR102878718 B1 KR 102878718B1 KR 1020247018848 A KR1020247018848 A KR 1020247018848A KR 20247018848 A KR20247018848 A KR 20247018848A KR 102878718 B1 KR102878718 B1 KR 102878718B1
Authority
KR
South Korea
Prior art keywords
amino acid
seq
acid sequence
antigen
human monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247018848A
Other languages
English (en)
Korean (ko)
Other versions
KR20240096746A (ko
Inventor
제이미 엠. 오렝고
앤드류 제이. 머피
아쇼크 티. 베디테
비샬 카맛
야슈 리우
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Publication of KR20240096746A publication Critical patent/KR20240096746A/ko
Application granted granted Critical
Publication of KR102878718B1 publication Critical patent/KR102878718B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020247018848A 2017-06-01 2018-05-31 Bet v 1에 대한 인간 항체 및 이것의 사용 방법 Active KR102878718B1 (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762513872P 2017-06-01 2017-06-01
US62/513,872 2017-06-01
US201762571696P 2017-10-12 2017-10-12
US62/571,696 2017-10-12
US201862662165P 2018-04-24 2018-04-24
US62/662,165 2018-04-24
KR1020217037411A KR102674000B1 (ko) 2017-06-01 2018-05-31 Bet v 1에 대한 인간 항체 및 이것의 사용 방법
PCT/US2018/035366 WO2018222854A1 (en) 2017-06-01 2018-05-31 Human antibodies to bet v 1 and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217037411A Division KR102674000B1 (ko) 2017-06-01 2018-05-31 Bet v 1에 대한 인간 항체 및 이것의 사용 방법

Publications (2)

Publication Number Publication Date
KR20240096746A KR20240096746A (ko) 2024-06-26
KR102878718B1 true KR102878718B1 (ko) 2025-10-31

Family

ID=62705709

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247018848A Active KR102878718B1 (ko) 2017-06-01 2018-05-31 Bet v 1에 대한 인간 항체 및 이것의 사용 방법
KR1020197036599A Active KR102329175B1 (ko) 2017-06-01 2018-05-31 Bet v 1에 대한 인간 항체 및 이것의 사용 방법
KR1020217037411A Active KR102674000B1 (ko) 2017-06-01 2018-05-31 Bet v 1에 대한 인간 항체 및 이것의 사용 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197036599A Active KR102329175B1 (ko) 2017-06-01 2018-05-31 Bet v 1에 대한 인간 항체 및 이것의 사용 방법
KR1020217037411A Active KR102674000B1 (ko) 2017-06-01 2018-05-31 Bet v 1에 대한 인간 항체 및 이것의 사용 방법

Country Status (17)

Country Link
US (3) US10793624B2 (https=)
EP (1) EP3630814A1 (https=)
JP (3) JP6963036B2 (https=)
KR (3) KR102878718B1 (https=)
CN (1) CN110997713B (https=)
AU (2) AU2018275657B2 (https=)
BR (1) BR112019025150B1 (https=)
CA (1) CA3063588A1 (https=)
CL (3) CL2019003508A1 (https=)
CO (1) CO2019013196A2 (https=)
IL (2) IL298034B2 (https=)
MX (2) MX2019014430A (https=)
MY (1) MY198270A (https=)
NZ (1) NZ759513A (https=)
PH (1) PH12019550238A1 (https=)
WO (1) WO2018222854A1 (https=)
ZA (1) ZA201907513B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107635527B (zh) 2015-03-10 2021-04-23 里珍纳龙药品有限公司 无菌刺穿系统和方法
KR102540409B1 (ko) 2017-05-05 2023-06-09 리제너론 파아마슈티컬스, 인크. 자동 주사기
IL298034B2 (en) 2017-06-01 2024-05-01 Regeneron Pharma Antibodies against BET V 1 and methods of using them
CA3177918A1 (en) * 2020-07-01 2022-01-06 Amanda ATANASIO Methods of treating allergy using anti-bet v 1 antibodies
CN113041271B (zh) * 2021-04-14 2022-12-27 浙江养生堂天然药物研究所有限公司 具有预防和抗过敏功效的组合物
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
CN118660719A (zh) * 2021-12-08 2024-09-17 艾吉尼克斯公司 用于过敏症疗法的组合
WO2024200854A1 (en) 2023-03-31 2024-10-03 Alk-Abelló A/S Allergen binding antibodies suitable for treating tree pollen allergies
WO2024251358A1 (en) 2023-06-07 2024-12-12 Mabylon Ag Anti-allergen antibodies and uses thereof
WO2024259313A1 (en) 2023-06-16 2024-12-19 Regeneron Pharamceuticals, Inc. Medical device packaging and related methods
US20250011403A1 (en) * 2023-07-03 2025-01-09 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-sp17 antibodies and other sp17 binding proteins
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
TW202529831A (zh) 2023-10-02 2025-08-01 美商再生元醫藥公司 藥物遞輸裝置安全系統
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
US20250255994A1 (en) * 2023-11-29 2025-08-14 Medicovestor, Inc. Dimeric immunoconjugates for use in treating cancers and methods of use
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US20250263471A1 (en) 2024-01-30 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-bet v 1 antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007134350A2 (en) 2006-05-18 2007-11-29 Biomay Ag Antibodies specific for bet v 1 and use thereof in the prevention and treatment of bet v 1-induced diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010194A2 (de) 1992-10-27 1994-05-11 Biomay Produktions- Und Handelsgesellschaft M.B.H. MOLEKÜLFRAGMENTE (PEPTIDE) DER HAUPTALLERGENE DER POLLEN VON BÄUMEN DER ORDNUNG $i(FAGALES)
WO1994014475A1 (en) 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
EP0619323A1 (en) 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
ITMI20052517A1 (it) * 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US10935554B2 (en) * 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
IL298034B2 (en) 2017-06-01 2024-05-01 Regeneron Pharma Antibodies against BET V 1 and methods of using them
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
CA3177918A1 (en) * 2020-07-01 2022-01-06 Amanda ATANASIO Methods of treating allergy using anti-bet v 1 antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007134350A2 (en) 2006-05-18 2007-11-29 Biomay Ag Antibodies specific for bet v 1 and use thereof in the prevention and treatment of bet v 1-induced diseases

Also Published As

Publication number Publication date
CL2021002850A1 (es) 2022-06-24
AU2018275657A1 (en) 2019-12-19
KR102329175B1 (ko) 2021-11-19
US20180346555A1 (en) 2018-12-06
JP2022174238A (ja) 2022-11-22
KR20240096746A (ko) 2024-06-26
MY198270A (en) 2023-08-18
WO2018222854A1 (en) 2018-12-06
AU2018275657B2 (en) 2022-01-06
IL270894B2 (en) 2023-04-01
KR20210143327A (ko) 2021-11-26
IL270894B (en) 2022-12-01
US11767358B2 (en) 2023-09-26
AU2022200272B2 (en) 2024-10-03
NZ759513A (en) 2022-01-28
BR112019025150A2 (pt) 2020-06-23
CO2019013196A2 (es) 2020-01-17
BR112019025150B1 (pt) 2022-11-08
KR20200012892A (ko) 2020-02-05
IL270894A (en) 2020-01-30
JP7162097B2 (ja) 2022-10-27
MX2023000390A (es) 2023-02-13
CL2019003508A1 (es) 2020-06-19
MX2019014430A (es) 2020-07-14
AU2022200272A1 (en) 2022-02-10
JP2021112207A (ja) 2021-08-05
JP7458453B2 (ja) 2024-03-29
PH12019550238A1 (en) 2020-10-19
JP2020523004A (ja) 2020-08-06
IL298034A (en) 2023-01-01
IL298034B1 (en) 2024-01-01
JP6963036B2 (ja) 2021-11-05
KR102674000B1 (ko) 2024-06-11
US20240083986A1 (en) 2024-03-14
NZ782911A (en) 2025-08-29
CN110997713B (zh) 2024-01-02
ZA201907513B (en) 2022-04-28
EP3630814A1 (en) 2020-04-08
CA3063588A1 (en) 2018-12-06
CN110997713A (zh) 2020-04-10
US10793624B2 (en) 2020-10-06
IL298034B2 (en) 2024-05-01
CL2021002851A1 (es) 2022-08-19
US20210054056A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
AU2022200272B2 (en) Human antibodies to Bet v 1 and methods of use thereof
CN110240651B (zh) 针对fel d1的人源抗体及其使用方法
US20230203141A1 (en) Methods of treating an allergy with allergen-specific monoclonal antibodies
KR101766701B1 (ko) 인간 프로테아제-활성화된 수용체-2에 대한 고친화도 인간 항체들
KR20140069331A (ko) 항-ＥｒｂＢ3 항체 및 이의 용도
EA049718B1 (ru) Фармацевтическая композиция, содержащая антитела человека к bet v 1, и способы ее применения
EA045437B1 (ru) Антитела человека к bet v 1 и способы их применения
BR122022004090B1 (pt) Composição farmacêutica, e, uso da composição farmacêutica
NZ782911A9 (en) Human antibodies to bet v 1 and methods of use thereof

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)